We accelerate drug discovery
Pharma R&D efficiency is decreasing steadily, while the cost of new drug discovery is increasing exponentially. Vast amounts of structured data are being generated by the use of high throughput technologies in drug discovery/development. However, the analysis and interpretation of this data for meaningful outcomes has been a challenge.
Peptris has developed a platform technology to enhance efficiencies across the drug discovery/development cascade using Artificial Intelligence/Machine Learning. Our neural network models aid us to rationalize and provide insights to experimental data in molecular biology and, further make predictions to generate hypothesis for newer experiments to be done
Our unique platform technology is not specific to any target, and aims to address a wide range of problems from predicting individual properties to analyze system interactions, including scenarios involving novel targets. The time, effort and money spent on new drug discovery can be optimized with the products that we are developing.
Predict binding affinity of small molecules targeting proteins for therapeutic purposes
Predict interaction scores of novel drug like peptide with target proteins
Re-purpose existing licensed drugs for new medical indications, since information about pharmacology, formulation and potential toxicity are available, drug development requires much lesser effort and can potentially reach clinical trials quickly
Our technology leverages cutting edge neural network architectures found in Natural Language Processing and Image processing research areas. We design and develop deep neural network models to learn from the vast amount of existing knowledge about proteins and small molecules. Our proprietary models are custom trained on a multitude of tasks specially designed to find generalized patterns and semantic representations of proteins and small molecules.
We have curated millions of data points including structure, annotations and properties data of Proteins, Molecules and Interactions from public data sources.
The learned representations of Proteins and Molecules from our pre-trained Multi-task networks enable us to predict binding affinities of protein-small molecule and protein-protein interactions. This fundamental tool makes it possible to accelerate drug discovery process,(discover,lead optimization,toxicity and specificty predictions) with unparalleled precision and accuracy.
We use very diverse set of data to train our models, and hence can be used to predict variety of properties of biological molecules and also for novel targets which donot have 3D structure. Such wide applicablility also enables prediction of selectivity and off-target toxicity
Our computational models work on cloud machines and deliver much faster than ultra high throughput screening. we can run our models to screen millions of compounds each day, and approach is fast enough to ensure screening for specificity as part of the pipeline.
Our deep neural network models provide far better accuracy than the current industry standards and we’re able to deliver accuracy comparable to wet lab experiments.
Our method is complementary to existing industry practices, and hence can be adopted very easily in the existing drug development process.
Venkat has more than 20 years of experience in Systems architecture and Software Development. Played a key role in all phases of the product in consumer electronics and professional displays. Venkat holds a Integrated M.Sc. in Mathematics and Computer Applications from IIT Delhi
Shridhar has over 15 years of experience in drug discovery and development in the Indian pharmaceutical industry. Shridhar holds a PhD in Pharmacology from Ohio State University, and has post-doctoral experience in Neuro-pharmacology at the University of California, Los Angeles.
Anand has about 20 years of experience in Digital Televisions, Image Processing, Data Analysis and NLP. Anand holds about 5 patents related LPD technology and display solutions Anand holds a B.E in Electronics and Communication from Gogte Institute of Technology, Belgaum.
Amit has over 18 years of experience in system and software development. His interests include algorithms, and basic sciences. He has worked on key algorithms for large format tiled video displays. Amit holds a B.E in Computer Science from NIT, Trichy.
Dr Nagasuma Chandra is the Co-Founder of HealthSeq Precision Medicine Private Limited and a Professor at the Department of Biochemistry, IISc, Bangalore, and has keen interest in studies of genome-scale molecular networks at different levels from systems to protein structures
Tapan An IIM Ahemadabad Alumnus and Ex-Flipkart VP-Finance, He brings is vast experience in setting up various companies health/food industry. He is our chief financial advisor and guides compay in financial matters and business development